News + Resources

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

Epigenetic editors are a gentler form of gene editing

February 24, 2025

The Economist

Epigenetic editors are a gentler form of gene editing

February 24, 2025

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

All Stories

News

Biotech Scribe strikes gene editing deal with Lilly subsidiary

May 16, 2023

Biopharma Dive

Read Now

Press Release

Biotech Scribe strikes gene editing deal with Lilly subsidiary

May 16, 2023

Biopharma Dive

Read Now

News

Lilly Subsidiary, Scribe Ink Up-to-$1.5B CRISPR-Based Neuro Collaboration

May 16, 2023

Genetic Engineering & Biotechnology News

Read Now

Press Release

Lilly Subsidiary, Scribe Ink Up-to-$1.5B CRISPR-Based Neuro Collaboration

May 16, 2023

Genetic Engineering & Biotechnology News

Read Now

News

Scribe's CRISPR tech Prevails in new $1.5B biobucks deal with Lilly unit

May 16, 2023

Fierce Biotech

Read Now

Press Release

Scribe's CRISPR tech Prevails in new $1.5B biobucks deal with Lilly unit

May 16, 2023

Fierce Biotech

Read Now

News

Scribe pens $1.5B-plus CRISPR tech deal with Lilly

May 16, 2023

BioWorld

Read Now

Press Release

Scribe pens $1.5B-plus CRISPR tech deal with Lilly

May 16, 2023

BioWorld

Read Now

News

Lilly, Scribe team up for neuro diseases CRISPR therapies in $75M upfront cash/equity deal

May 16, 2023

Seeking Alpha

Read Now

Press Release

Lilly, Scribe team up for neuro diseases CRISPR therapies in $75M upfront cash/equity deal

May 16, 2023

Seeking Alpha

Read Now

News

Growing East Bay biotech Scribe Therapeutics lines up potential $1.5 billion CRISPR deal

May 16, 2023

San Francisco Business Times

Read Now

Press Release

Growing East Bay biotech Scribe Therapeutics lines up potential $1.5 billion CRISPR deal

May 16, 2023

San Francisco Business Times

Read Now

News

Engineering CRISPR with Ben Oakes

April 8, 2021

Andreessen Horowitz

Read Now

News

The 20(+1) under 40: Inside the next generation of biotech leaders

April 6, 2021

Endpoints News

Read Now

News

Scribe Therapeutics continues to advance the development of its CRISPR platform and pipeline

April 1, 2021

PMLive

Read Now

News

Doudna’s Scribe Rewrites CRISPR Drug Development with $100 Million Series B

March 31, 2021

Genetic Engineering & Biotechnology News

Read Now

News

Scribe closes $100M series B round for gene editing rewrite

March 31, 2021

BioWorld

Read Now

News

Scribe Therapeutics Closes Series B Round With $100M To Target Gene Editing

March 31, 2021

Crunchbase News

Read Now

Press release

Scribe Therapeutics Expands In Vivo Collaboration with Sanofi to Second Target

January 3, 2024

Read Now

Press release

Scribe Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Read Now

Press release

Scribe Therapeutics Appoints Dr. Aarif Khakoo as Chief Scientific Officer and Head of Research and Development, and Dr. Maria Mirotsou as Vice President of Discovery Biology

December 20, 2023

Read Now

Press release

Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases

July 17, 2023

Read Now

Press release

Scribe Therapeutics to Participate in Upcoming Investor Conferences in May and June

May 22, 2023

Read Now

Press release

Scribe Therapeutics Presents Data on its X-Editing Technologies at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 19, 2023

Read Now

Publications and presentations

Presentation

Scribe Corporate Deck 2025 Q1

February 3, 2025

Read Now

Publication

CasX enzymes comprise a distinct family of RNA-guided genome editors

February 4, 2019

Nature

Read Now

Publication

Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes

May 1, 2017

Nature Biotechnology

Read Now

Publication

Targeted gene knock-in by homology-directed genome editing using Cas9 ribonucleoprotein and AAV donor delivery

March 2, 2017

Nucleic Acids Research

Read Now

Publication

Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch

June 1, 2016

Nature Biotechnology

Read Now

Publication

Multi-reporter selection for the design of active and more specific zinc-finger nucleases for genome editing

January 7, 2016

Nature Communications

Read Now

Publication

Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery

December 15, 2014

eLife

Read Now

Publication

Programmable RNA recognition and cleavage by CRISPR/Cas9

December 11, 2014

Nature

Read Now

Publication

MicroRNA-mediated switching of chromatin-remodelling complexes in neural development

July 30, 2009

Nature

Read Now